Darzalex ®▼(daratumumab) in Combination with Lenalidomide and Dexamethasone approved for reimbursement in Ireland for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible

Janssen, the Pharmaceutical Companies of Johnson & Johnson, announced today that Darzalex ^®(daratumumab) in combination with lenalidomide and dexamethasone (DRd) has been reimbursed in Ireland for the treatment of newly diagnosed multiple myeloma patients who are ineligible for autologous stem cell transplant (ASCT). Since launch, daratumumab has been used to treat more than 484,000 patients worldwide.²

The approval follows results from the Phase 3 MAIA (MMY3008) study, published in The New England Journal of Medicine ³ in 2019 and presented at the American Society of Hematology (ASH) Annual Meeting in 2018, with updated efficacy data in 2022.⁴